

## Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment

Hongjuan Zhang<sup>1,2</sup>, Cheng Zhan<sup>2</sup>, Ji Ke<sup>3</sup>, Zhiqiang Xue<sup>4</sup>, Aiqun Zhang<sup>4</sup>, Kaifeng Xu<sup>5</sup>, Zhirong Shen<sup>2,6</sup>, Lei Yu<sup>3</sup> and Liang Chen<sup>2,7</sup>

<sup>1</sup> School of Life Science, Tsinghua University, Beijing 100084, China

<sup>2</sup> National Institute of Biological Sciences, Beijing 102206, China

<sup>3</sup> Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China

<sup>4</sup> The General Hospital of People's Liberation Army (301 Hospital), Beijing 100853, China

<sup>5</sup> Peking Union Medical College Hospital, Beijing 100730, China

<sup>6</sup> Collaborative Innovation Center of Systems Biomedicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China

<sup>7</sup> National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, 102206, China

**Published:** October 16, 2018

**This article has been corrected:** The correct Acknowledgment information is given below:

### ACKNOWLEDGMENT

This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 2016; 7:3367-3378. <https://doi.org/10.18632/oncotarget.6491>